I agree that just the short time Dr Malan was with QMC would be enough for him to understand the nuances of integration of any special QD for biotech applications. QMC would have gained knowledge of his needs in QD and in QMCH adaption to clinical trial capabilities for all stages. One difference would be QMCH would be a distributed, non-centralized DLT with far more flexibility in linking different trials. It could be the center of a clinical trial ecosystem, a very large market itself.

In that sense, I see the move benefiting all parties in creating more products and more need for QMC HEALTHID type software. QMC will not be in the biotech research business but will defer to Innova in that area.

Innova is a better match for him to further develop stem cell based assays and treatments especially as they are in larger quarters and can build labs to suit the work to be done most efficiently, as well as having an existing R&D scientist base. It makes total sense.

I can even see the idea for the move might have come from QMC management itself, rather than Innova because Squires has built a team that does look far into the future. They hired Dr Malan, and saw his best use was at Innova, maybe, and IMO. The move seems to be an amiable one.

QMC loses future clinical research business and perhaps future Malan intellectual properties yet to be patented, depending on what the employment agreement states. That has value, and long story short, makes me think there is an unrevealed quid pro quo negotiated in favor of QMC, just like when ball teams trade players. IOW, I think QMC got something of value in return.